Home » Posts tagged 'texrad' (Page 2)
Tag Archives: texrad
Paper from TexRAD collaboration with Neuroradiologists presented at BSNR conference at Queens’ College, Cambridge – Feedback (FDBK)
The first output from the collaboration between TexRAD and Neuroradiologists from the prestigious National Hospital for Neurology and Neurosurgery, Queens Square, London, UK was presented at the British Society of Neuroradiologists annual conference at Queens’ College, Cambridge, 15th to 16th September 2017. Conference website here
The paper entitled – “Volumetric texture analysis of clinical MR imaging for identification of IDH wild type glioma” was presented by M Lewis (presenting-author), B Ganeshan, A Barnes, L Mancini, S Bisdas, A Groves, R Endozo and S Thust.
Dr Balaji Ganeshan presents TexRAD at the prestigious Beijing Society of Radiology Conference – Feedback Plc (FDBK).
Dr Balaji Ganeshan presents TexRAD at the prestigious Beijing Society of Radiology Conference.
On Saturday September 9th 2017, Dr Balaji Ganeshan, CEO of TexRAD Ltd and Director of New Business at Feedback Plc gave a keynote lecture entitled “TexRAD Texture Analysis of CT and MR images – ready for prime time?” at the prestigious Beijing Radiation Academic Annual Conference.
Dr. Ganeshan spoke on CT and MRI texture analysis in cancer imaging which is a very topical area of interest in medical imaging and TexRAD is at the forefront of this development. Evidence that currently supports the potential use of TexRAD in different clinical applications and its utility as part of the qualification process for its use in routine clinical practice was further discussed.
Pictures below show Dr Ganeshan receiving a Certificate of Appreciation from Professor H.D.Xue – Assistant Director of Radiology at Peking Union Medical College Hospital and a Committee member of the Beijing Society of Radiology.
Pictures below show Dr Ganeshan with Xiaowei Ni, CEO of Boya Digital Technology (Beijing) Co. Ltd, and members of the GE-China team including Zhuang Wei, Director of HCIT-GE-China. Dr Ganeshan is also shown with members of the GE-China team outside Beijing University Third Hospital.
Cancer Care Commission (CCC) is a UK company based in Oxford working with NHS trusts to help improve their clinical pathways for cancer care. CCC are partnering with China Resources Phoenix Health Group (CRPHG), who are a very large company owning over a hundred health facilities. CRPHG own Beijing-Yanhua-Hospital, and are partnering with Beijing 5th cancer hospital and CCC to try and create a centre of excellence for cancer care in North China. Pictures below show Dr Ganeshan presenting TexRAD with Boya CEO Xiaowei Ni, Dr Fred Sun, Sudhakar Jayaram, Dr Hongxia Yu and Dr Dadong Li, UK Trade & Investment Manager, Life Science. Dr Li’s team organised the meeting at Yanhua hospital.
TexRAD Texture Analysis of CT and MR images – ready for prime time at Beijing Radiation Academic Annual Conference – Feedback (FDBK)
Balaji Ganeshan, CEO of TexRAD and Director of New Business for Feedback plc our parent company, is presenting a session entitled “TexRAD Texture Analysis of CT and MR images – ready for prime time?” at the prestigious Beijing Radiation Academic Annual Conference starting September 9th. This part of our ongoing development of awareness of the importance of textural analysis and the features of TexRAD.
Feedback (FDBK) subsidiary CCI signs exclusive agreement with Boya Digital Technology (Beijing) to distribute TexRAD in China
Feedback plc is pleased to announce that its subsidiary, Cambridge Computed Imaging Ltd, has signed an exclusive distributor agreement with Boya Digital Technology (Beijing) Co. Ltd., based in Beijing, China, for sales and distribution of its TexRAD® texture analysis research software in the People’s Republic of China. Boya is an approved vendor to GE Healthcare China, Beijing and is facilitating the purchase and installation process of TexRAD research software on behalf of GE in the PRC.
TexRAD will be used by customers for research purposes, performing advanced analysis of routinely acquired medical diagnostic images (e.g. CT, MRI). As in western countries, university hospitals and research institutions in China are increasingly using innovative software such as TexRAD to generate new knowledge and insights in the fight against cancer and other diseases. The Agreement ensures user access and customer support for TexRAD within the rapidly growing market for medical research in the PRC.
Feedback regards the completion of this Agreement as a significant step in the continuing development of its global sales and market presence as outlined in recent investor presentations.
Dr Balaji Ganeshan, CEO of TexRAD Ltd and Director of New Business at Feedback Plc said; “We are delighted to have formalised the business relationship with both Boya and GE. This follows discussions at the Beijing Society of Radiology in 2016 and involvement in the installation of TexRAD software in a leading medical institution, Peking Union Medical College Hospital, Beijing. I look forward to working with Boya and GE to develop awareness of the capabilities of TexRAD and sales to the medical research community in China.”
Ian McLellan, Commercial Director CCI Ltd commented; “The signing of this Agreement with Boya represents an excellent basis on which to develop our sales and presence in this exciting growth market using the expertise and customer reach of Boya Digital Technologies. We look forward to developing the TexRAD revenue potential and increasing the market reach to our users.”
Ni Xiaowei, President Boya Digital Technologies confirmed; “We are pleased with the addition of TexRAD to our software portfolio, and look forward to working with CCI to promote this texture analysis software to research institutes in leading hospitals within the People’s Republic of China. I anticipate a very successful business relationship, working closely with Dr Balaji Ganeshan and CCI. Boya Digital Technologies has developed a strong reputation for IT sales and support with our customers which we can offer to support the development of TexRAD sales in China.”
|
Feedback plc
|
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker)
|
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker)
|
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
|
Brand Communications |
Tel: 07976 431608 |
About CCI
CCI Ltd is owned by AIM listed Feedback Plc (FDBK), based in Bourn, Cambridge UK. CCI focusses on the development and supply of advanced software including TexRAD, for texture analysis of medical images and storage and interpretation of imaging data.
About Boya
Boya Digital Technologies, founded in 2004 is based in Beijing, China and has been a manufacturer and supplier of computers, peripherals and software for over 10 years. It is a re-seller and vendor to a number of companies in China. Boya is part of the larger corporate organization, Boya Software Co Ltd, which aims to create value for its customers through technology and services.
About TexRAD
TexRAD is a highly advanced, patented image texture analysis software tool that analyses the textures in routinely acquired diagnostic medical images (e.g. CT, MRI) to reveal features that are not always evident to the human eye. The platform also comprises a novel data-mining tool to assist the research customer to undertake statistical analysis to identify interesting parameters demonstrating association with patient outcome and clinical parameters. A number of research studies published in numerous peer-reviewed journals and conference presentations show that TexRAD texture metrics may have the potential to predict prognosis, disease severity and treatment prediction/evaluation in a number of cancer applications. TexRAD is manufactured under licence by the ISO 13485 certified company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc.
Commercial Director appointed for CCI Ltd – Feedback (FDBK)
Feedback plc are pleased to welcome Ian McLellan as Commercial Director for CCI Ltd. This new role will develop the market and sales channels for our products, supporting sales growth including the launch of next generation TexRAD products as part our commitment to invest in our Brands.
Ian has joined CCI after working closely with the management team over the last six months in a consultancy role to develop our strategy and Commercial structure.
Experienced in both global Corporate and small company environments as well as the NHS, he brings international sales and strategic marketing expertise in nuclear medicine and imaging modalities acquired from GE Healthcare, where he had senior roles in market development and as UK Marketing Manager. Ian also brings a track record of successful licensing and distribution agreements to support our business growth, having in-licensed two ground-breaking nuclear imaging agents whilst at Amersham Healthcare.
His career has involved interaction with stakeholders and users at all levels and this appointment will provide significant additional resource and expertise as CCI seek relationships, local distributors and a widening customer base.
Ian McLellan commented “I have been impressed with the technology and expertise within CCI, and I am pleased to be joining at this exciting time in the Company history as we develop new growth opportunities through product innovation and wider sales channels.”
CCI Ltd CEO Mike Hayball observed “We welcome Ian to the management team. He has brought significant expertise to our strategy development and his experience of developing new markets and product launches will enhance our ability to generate growth and strengthen user awareness of our technology.”
Feedback (FDBK) – Issue of equity to TexRAD founder
Feedback plc (AIM: FDBK), the medical imaging software company, announces that it has today issued 350,000 ordinary shares of 0.25 pence each pursuant to an exercise of warrants by a founder of TexRAD Limited, conditional on admission of the Warrant Shares to trading on AIM. The Warrants Shares were converted a price of 1.25 pence per ordinary share.
Application has been made for the Warrant Shares to be admitted to trading on AIM and it is expected that admission will take place on 6 July 2017.
Following admission of the Warrant Shares to trading on AIM, the Company’s issued ordinary share capital will consist of 246,416,584 ordinary shares, with one voting right per share. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company is 246,416,584.
The above figure may be used by shareholders in the Company as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.
For further information contact:
|
Feedback plc |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
Endometrial Carcinoma: MR Imaging-based Texture Model for Preoperative Risk Stratification – Feedback (FDBK).
Feedback (FDBK) – Endometrial Carcinoma: MR Imaging-based Texture Model for Preoperative Risk Stratification – Preliminary Analysis. Source 
Ueno Y, et al. Radiology. 2017.
PURPOSE: To evaluate the associations among mathematical modeling with the use of magnetic resonance (MR) imaging-based texture features and deep myometrial invasion (DMI), lymphovascular space invasion (LVSI), and histologic high-grade endometrial carcinoma.
MATERIALS & METHODS: Institutional review board approval was obtained for this retrospective study. This study included 137 women with endometrial carcinomas measuring greater than 1 cm in maximal diameter who underwent 1.5-T MR imaging before hysterectomy between January 2011 and December 2015. Texture analysis was performed with commercial research software (TexRAD) with manual delineation of a region of interest around the tumor on MR images (T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced images and apparent diffusion coefficient maps). Areas under the receiver operating characteristic curveand diagnostic performance of random forest models determined by using a subset of the most relevant texture features were estimated and compared with those of independent and blinded visual assessments by three subspecialty radiologists.
RESULTS: A total of 180 texture features were extracted and ultimately limited to 11 features for DMI, 12 for LVSI, and 16 for high-grade tumor for random forest modeling. With random forest models, areas under the receiver operating characteristic curve, sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were estimated at 0.84, 79.3%, 82.3%, 81.0%, 76.7%, and 84.4% for DMI; 0.80, 80.9%, 72.5%, 76.6%, 74.3%, and 79.4% for LVSI; and 0.83, 81.0%, 76.8%, 78.1%, 60.7%, and 90.1% for high-grade tumor, respectively. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of visual assessment for DMI were 84.5%, 82.3%, 83.2%, 77.7%, and 87.8% (reader 3).
CONCLUSION: The mathematical models that incorporated MR imaging-based texture features were associated with the presence of DMI, LVSI, and high-grade tumor and achieved equivalent accuracy to that of subspecialty radiologists for assessment of DMI in endometrial cancers larger than 1 cm. However, these preliminary results must be interpreted with caution until they are validated with an independent data set, because the small sample size relative to the number of features extracted may have resulted in overfitting of the models.
Copyright © 2017 The RSNA. All rights reserved.
Original article link here
Prostate-specific membrane antigen PET-MRI validation of MR textural analysis for detection of transition zone prostate cancer? – Feedback (FDBK)
Feedback (FDBK) – Prostate-specific membrane antigen PET/MRI validation of MR textural analysis for detection of transition zone prostate cancer? Source
Bates A, et al. Eur Radiol. 2017.
OBJECTIVES: To validate MR textural analysis (MRTA) for detection of transition zone (TZ) prostate cancer through comparison with co-registered prostate-specific membrane antigen (PSMA) PET-MR.
METHODS: Retrospective analysis was performed for 30 men who underwent simultaneous PSMA PET-MR imaging for staging of prostate cancer. Thirty texture features were derived from each manually contoured T2-weighted, transaxial, prostatic TZ using texture analysis software that applies a spatial band-pass filter and quantifies texture through histogram analysis. Texture features of the TZ were compared to PSMA expression on the corresponding PET images. The Benjamini-Hochberg correction controlled the false discovery rate at <5%.
RESULTS: Eighty-eight T2-weighted images in 18 patients demonstrated abnormal PSMA expression within the TZ on PET-MR. 123 images were PSMA negative. Based on the corrected p-value of 0.005, significant differences between PSMA positive and negative slices were found for 16 texture parameters: Standard deviation and mean of positive pixels for all spatial filters (p = <0.0001 for both at all spatial scaling factor (SSF) values) and mean intensity following filtration for SSF 3-6 mm (p = 0.0002-0.0018).
CONCLUSION: Abnormal expression of PSMA within the TZ is associated with altered texture on T2-weighted MR, providing validation of MRTA for the detection of TZ prostate cancer.
KEY POINTS: Prostate transition zone (TZ) MR texture analysis may assist in prostate cancer detection. • Abnormal transition zone PSMA expression correlates with altered texture on T2-weighted MR. • TZ with abnormal PSMA expression demonstrates significantly reduced MI, SD and MPP.
Copyright © 2017 The Royal College of Radiologists. All rights reserved.
Original article link here
Can TexRAD CT measures of tumour heterogeneity stratify risk for nodal metastasis in patients with non-small cell lung cancer? – Feedback (FDBK)
Feedback (FDBK) – Can CT measures of tumour heterogeneity stratify risk for nodal metastasis in patients with non-small cell lung cancer? Source
Can CT measures of tumour heterogeneity stratify risk for nodal metastasis in patients with non-small cell lung cancer?.
Craigie M, et al. Clinical Radiology. 2017.
AIM: To undertake a preliminary assessment of the potential for computed tomography (CT) measurement of tumour heterogeneity to stratify risk of nodal metastasis in patients with non-small cell lung cancer (NSCLC).
MATERIALS & METHODS: Tumour heterogeneity in CT images from combined positron-emission tomography (PET)/CT examinations in 150 consecutive patients with NSCLC was assessed using CT texture analysis (CTTA). The short axis diameter of the largest mediastinal node was also measured. Forty-two patients without distant metastases subsequently had tumour nodal status confirmed at surgery (n=26) or endobronchial ultrasound (EBUS; n=16). CTTA parameters and largest nodal diameter were related to nodal status using the rank correlation and the risk ratio for each nodal stage (>N0, >N1, >N2) was compared between patients categorised as high and low risk by CTTA or nodal size. The most significant predictor of nodal status was related to overall survival using Kaplan-Meier analysis.
RESULTS: N-stage was more significantly correlated with CTTA than nodal diameter (Rs = -0.39, p=0.011, Rs = -0.45, p=0.0025, Rs = -0.40, p=0.0091 for normalised standard deviation (SD), normalised entropy and kurtosis respectively; Rs = -0.39, p=0.042 for nodal diameter). The presence of two or more high-risk CTTA values was the greatest risk factor for mediastinal metastasis (risk ratio: 11.0, 95% confidence interval: 1.56-77.8, p=0.0014) and was associated with significantly poorer overall survival (p=0.016).
CONCLUSION: CTTA in NSCLC is related to nodal status in patients without distant metastases and has the potential to inform selection of investigative strategies for the assessment of mediastinal malignancy.
Copyright © 2017 The Royal College of Radiologists. All rights reserved.
Original article link here
Feedback (FDBK) subsidiary Cambridge Computed Imaging announces exclusive distributor arrangement with Korea Computer Motion ISG
Feedback plc subsidiary Cambridge Computed Imaging Ltd (CCI) is pleased to announce the signing of an Exclusive Distributor arrangement with Korea Computer Motion ISG (Korea ISG) based in Seoul, South Korea for sales and distribution of its TexRAD® texture analysis research software.
TexRAD will be used by customers for research purposes, performing advanced analysis of routinely acquired medical diagnostic images (e.g. CT, MRI) in South Korea.
As outlined in our recent investor presentations, this is a significant step for CCI Ltd as part of its plans to expand sales of TexRAD software to meet the fast-growing demand in Asian markets, identifying and engaging with distributors who are experts in the local market, and who can leverage the TexRAD brand awareness to help build a regional sales pipeline.
Dr Balaji Ganeshan, CEO of TexRAD Ltd and Director of New Business at Feedback Plc said; “We are pleased to sign this significant Distributorship agreement with Korea ISG to support the interest and acceptance of TexRAD in the rapidly growing and important South Korean medical imaging research market. We are confident that by working with an experienced team led by the CEO Jacob Woo, who has a great understanding of the market and customer base, we stand to increase the TexRAD revenue potential and market reach and meet our customer needs.”
Mr Jacob Woo, CEO of Korea ISG commented; “We are pleased to have started to work with CCI Ltd this year to promote the highly acclaimed TexRAD texture analysis software in South Korea which has attracted a lot of interest amongst the top University Hospitals who are also our potential-customers. Following a recent installation for research at the prestigious Korea University Hospital, I anticipate a very successful business relationship, rapidly increasing TexRAD software sales and working closely with Dr. Balaji Ganeshan and CCI. Our team has a first class reputation amongst researchers in the region, and offers unrivalled in-depth market-access and know-how in South Korea.”
About CCI
CCI Ltd is owned by AIM listed Feedback Plc (FDBK), based in Bourn, Cambridge UK. CCI focusses on the development and supply of advanced software including TexRAD, for texture analysis of medical images and storage and interpretation of imaging data.
About Korea Motion ISG
Korea ISG has installed and supported MRI/CT 3D processing imaging software to about 120 prominent Korean hospitals for 23 years, and is the largest medical imaging software distribution (sales and service/support) company in South Korea. They are experienced distributors of medical software from other world leading suppliers, with a wide customer base.
About TexRAD
TexRAD is a highly advanced, patented image texture analysis software tool that analyses routinely acquired diagnostic medical images (e.g. CT, MRI) to reveal features that are not always evident to the human eye. The platform also comprises a novel data-mining tool to assist the research customer to undertake statistical analysis to identify interesting parameters demonstrating association with patient outcome and clinical parameters. A number of research studies published in numerous peer-reviewed journals and conference presentations show that TexRAD texture metrics may have the potential to predict prognosis, disease severity and treatment prediction/evaluation in a number of cancer applications.
Contact for press enquiries
CCI Ltd: Mike Hayball, CEO Tel: 01954 718055
TexRAD Ltd: Dr. Balaji Ganeshan, CEO Tel: 01954 718072
Feedback plc: Alastair Riddell, Chairman Tel: 01954 718072
Brand Communications: Alan Green Tel: 07976 431608